Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Terran Biosciences and Blumentech S.L. Announce the Acquisition of a Patent Portfolio Covering the Groundbreaking Discoveries of Prominent Psychedelics Researcher Dr. Jordi Riba","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Terran Biosciences Announces Licensing Deal with Sanofi for Two Late-Stage CNS Pipeline Assets ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terran Biosciences Announces Publication Of PCT Patent Applications Covering Orally Active Forms Of DMT and 5-MeO-DMT And Long-Acting MDMA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Terran Biosciences Announces Exclusive Licensing Deal with Pierre Fabre for Idazoxan; Terran Completes Key Development Milestones","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Terran Biosciences

    Menu

    Terran Biosciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Terran Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Terran Biosciences Announces Exclusive Licensing Deal with Pierre Fabre for Idazoxan; Terran Completes Key Development Milestones

              Details:

              Under the agreement, Terran obtains exclusive global development and commercialization rights for idazoxan hydrochloride, a selective alpha 2 receptor antagonist and a late-stage clinical therapeutic for the treatment of schizophrenia.

              Lead Product(s): Idazoxan

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: Pierre Fabre

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement June 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Terran Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Terran Biosciences Announces Publication Of PCT Patent Applications Covering Orally Active Forms Of DMT and 5-MeO-DMT And Long-Acting MDMA

              Details:

              N,N-dimethyltryptamine is a psychedelic tryptamine, non-selective agonist for 5HT2a receptor being developed as a therapy for patients with neurological & mental illness.

              Lead Product(s): Dimethyltryptamine

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Terran Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Terran Biosciences Announces Licensing Deal with Sanofi for Two Late-Stage CNS Pipeline Assets

              Details:

              Terran plans to quickly advance the development of the lead SAR442168 and other assets for neurological and psychiatric indications, which include several novel applications where there is a large unmet medical need.

              Lead Product(s): Tolebrutinib

              Therapeutic Area: Neurology Product Name: SAR442168

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sanofi

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement April 21, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Terran Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Terran Biosciences and Blumentech S.L. Announce the Acquisition of a Patent Portfolio Covering the Groundbreaking Discoveries of Prominent Psychedelics Researcher Dr. Jordi...

              Details:

              Blumentech's patents further complement Terran's rapidly growing IP portfolio of over 150 patent applications in the psychedelic space, which includes patents on Terran's orally-active DMT compound, a product of Terran's robust medicinal chemistry drug discovery program.

              Lead Product(s): Dimethyltryptamine

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: Blumentech S.L.

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement April 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY